Kornimate/medical-research-clean huggingface dataset:
nifedipine gits and amlodipine besylate on recovery of blood pressure rhythm and arterial stiffness

Conditions: Hypertension

Summary: this trial evaluates the effects of nifedipine gits and amlodipine besylate on blood pressure rhythm restoration and arterial stiffness in young and middle-aged non-dipper hypertensives. half of participants will receive nifedipine gits, half of half will take medicine in the morning or at night. while the other half participants will take amlodipine besylate, whom will also be assigned taking medicine in the morning or at night. ambulatory blood pressure monitoring and arterial stiffness examination will be performed before and after pharmaceutical intervention.

written informed consent will obtained from all the participants. all the adverse reaction or adverse event, related or unrelated to the study drug, will be recorded in detail, including the occurrence time, symptoms and vital signs, degree, duration, laboratory test indexes, treatment methods and results, process, follow-up time, etc. if serious adverse event occurs, study drugs should be stopped and necessary remedy should be delivered immediately. at the same time, the investigator must report it to the local drug supervision, medical ethics committee and china food and drug administration. -

Eligibility criteria:
inclusion criteria: * mild to moderate (office blood pressure : 140 mmhg =\ =0.9 and night-time mean sbp \>=120 mmhg) hypertensive subjects, who is drug treatment-naive or previously treated but discontinued for 2 weeks or more * the subject is voluntary to participate in the study and has signed the informed consent form exclusion criteria: * known allergy to any component of nifedipine and amlodipine * office sbp \>=180 mmhg and / or dbp \>=110 mmhg in the screening period * the patient who is taking calcium antagonists (monotherapy or combination with other drugs) * evidences of secondary hypertension * history of cerebrovascular events, cardiac failure, serious coronary artery disease within 12 months * type 1 diabetes mellitus (dm) * severe liver diseases or renal insufficiency * the pregnant woman, the woman who may be pregnant or plan to be pregnant, or the lactating woman * the subject who needs to work at night (on night shift) * other reasons that the subject can not participate in the study

Keywords: non-dipper hypertension young middle-aged ambulatory blood pressure monitoring arterial stiffness nifedipine gastrointestinal therapeutic system (gits)
the laparoscopic and endoscopic cooperative surgery of gastrointestinal stromal tumor

Conditions: Gastrointestinal Stromal Tumor

Summary: gastric stromal tumor is a gastrointestinal mesenchymal tumor with malignant differentiation potential, the incidence increased year by year. the surgical resection is the primary treatment for it. although laparoscopic gist resection has many benefits，due to in lack of the delicate sense of touch, it could lead to the incomplete resection and disorders of digestion. more than 33% of postoperative patients have the gastric dysfunction. laparoscopic endoscopy combined surgery is different from the past technology. it is a new radical resection of gist presented by japanese scholars. lecs resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .this method conforms to the idea of the modern minimally invasive surgery, and avoids many problems，such as incomplete resection and disorders of digestion caused by excessive tissue resection. our team will spearhead the gist treatment of lecs. first of all, the investigators will collect 120 cases of gist patients, randomly assigned for the laparoscopic group, the lecs, single-arch the lecs surgical treatment. secondly, to analyzing the basic treatment and follow-up data, including the operation time, blood loss, the number of transfer laparotomy, the number of cut edge positive, the distances of cut edge away from the tumor edge, the cases of anastomotic fistula bleeding, stenosis, average such confinement, the meal time, cost of treatment, tumor recurrence rate, the presence of residual stomach, upset stomach and frequency, reflux esophagitis, bile reflux gastritis and other indicators.the purpose of this subject is to observe the effectivity and safety of lecs and single-arch the lecs, invent serval lecs equipment patents and provide some references for lecs applying to the minimally invasive surgery of the digestive tract tumor and multidisciplinary treatment mode .


Eligibility criteria:
inclusion criteria: * patients without contraindications gastroscope，surgery and anesthesia; * gastroscope found submucosal lesions, qualitative hard;endoscopic ultrasonography (eus) confirmed the lesions come from the muscularis propria * tumors diameter \> 2 cm;or tumors had \< 2 cm, but the position is located in the stomach wall, after nearly cardia and it is a difficult position for gastroscope ; * tumors diameter \< 5 cm, the tumors had complete, no broken feed and bleeding * not found the tumor metastasis * there is no history of abdominal surgery, no severe abdominal cavity adhesion * patients signed informed consent exclusion criteria: * patients with preoperative assessment of distant metastasis; * patients with preoperative radiation and chemotherapy or hormone therapy; * patients with acute obstruction, bleeding or perforation of the emergency surgery * patients with a history of abdominal trauma or abdominal surgery. * patients with contraindications gastroscope，surgery and anesthesia;
pharmacological postconditioning to reduce infarct size following primary pci

Conditions: Myocardial Infarction

Summary: both pre- and postconditioning seem to protect cardiomyocytes during reperfusion therapy. investigations both ex vivo and in vivo suggest that a gut derived hormone, glucagon-like-peptide-1 (glp-1), is able to reduce reperfusioninjury after myocardial ischemia. results from our own laboratory have shown a marked reduction in infarct size when rat hearts in a langendorf preparation were exposed to the glp-1 analogue, exendin-4. the investigators want to investigate to what extent this effect can be translated to humans in the setting of acute stemi treated with primary pci when evalutaed by cardiac magnetic resonance imaging.


Eligibility criteria:
inclusion criteria: * more than 18 years of age. * stemi less than 12 hours from onset of pain. stemi defined as as st-segment elevation in 2 contiguous electrocardiographic leads of \>0.1 mv in v4 - v6 or limb leads ii, iii and avf, or \>0.2 mv in lead v1 - v3. * timi 0-1 in infarct related artery. * oral and written informed consent. exclusion criteria: * multivessel disease defined by one or more stenoses \>70% in diameter in the non infarct related artery. * previous myocardial infarction. * stent trombosis. * previous cabg. * less than timi 2 following wiring and predilatation of the infarct related artery but prior to postconditioning or placebo treatment. * renal insufficiency (creatinin \>200). * pregnancy or lactation. * diabetic ketoacidose eller hypoglycemia (plasma glukose \< 2.5 mmol/l). * pancreatitis.

Keywords: st-segment elevation myocardial infarction primary pci postconditioning
effect of an enhanced recovery after surgery program on outcomes after pancreatoduodenectomy

Conditions: Pancreatectomy; Enhanced Recovery After Surgery; Pancreatic Cancer Resectable

Summary: this study assesses whether patients with pancreatic cancer who undergo surgery experience improved outcomes following the implementation of a multidisciplinary care pathway, specifically an enhanced recovery after surgery (eras) program. this pathway includes various interventions in the preoperative, intraoperative, and postoperative care of these patients, all aimed at enhancing their health status and postoperative results.

this prospective observational study is conducted by the same surgical team at two high-volume pancreatic cancer referral centers in greece. patients undergoing elective pancreatic surgery are prospectively enrolled and managed according to a standardized eras protocol (eras group). a control group, which received standard perioperative care before the implementation of eras, was retrospectively selected and matched based on demographic and clinical parameters. the primary study endpoint is the length of hospital stay (los), while secondary endpoints include 30-day mortality and morbidity.

Eligibility criteria:
inclusion criteria: * adult patients * diagnosis of pancreatic cancer * elective open pancreatic surgery exclusion criteria: * age \<18 years * emergency pancreatic surgery * other surgical procedures * missing data * lost to follow-up

Keywords: pancreatectomy enhanced recovery after surgery pancreatic cancer resectable outcomes research
effectiveness of behavioral activation treatment for schizophrenia

Conditions: Schizophrenia, Latent; Negative Symptoms in Schizophrenia; Behavioral Activation; Remote Medical Service

Summary: the purpose of this study is to implement a behavior activation remote program for negative symptoms of schizophrenia and to verify whether the behavior activation remote program for negative symptoms of schizophrenia has effects on negative symptoms, cognitive function, and social function of schizophrenia.


Eligibility criteria:
inclusion criteria: * patients who have received a primary diagnosis of schizophrenia * patients who are at least 18 years old and under 65 years old * patients who show a score of 3 or higher on at least two negative symptom items in the positive and negative syndrome scale (panss) * the subject selection period is until december 31, 2021, from the irb approval date. exclusion criteria: * patients with a history of organic brain syndrome, epilepsy, or traumatic brain injury * patients with comorbidities such as intellectual disability, current alcohol or other substance dependence * patients who show a score of 5 or higher on at least two positive symptom items in the positive and negative syndrome scale (panss) * patients who have received a diagnosis of major depressive disorder according to the dsm-v criteria by a specialist in psychiatry * patients who have received psychological services including components of behavioral activation therapy * patients who are at risk of self-harm or harm to others.

Keywords: schizophrenia negative symptoms in schizophrenia behavioral activation remote medical service
incremental dialysis to improve health outcomes in people starting haemodialysis (inch-hd)

Conditions: Kidney Failure

Summary: the inch-hd trial will test if incremental hd preserves the quality of life of patients and families and is a safe, practical, cost effective treatment option.

kidney failure is a growing public health problem and fatal unless treated with dialysis or transplantation. haemodialysis is the most common treatment for kidney failure in australia and globally. patients find haemodialysis extremely burdensome due to symptoms like fatigue, pain, cramps and poor quality of life that generally equates to \<60% of full health. furthermore, haemodialysis is associated with an extremely high mortality (\<50% survive 5 years), particularly in the first 3-6 months of starting haemodialysis, which is likely linked to the rapid loss of patients' own kidney function when starting haemodialysis abruptly at three sessions/week. observational studies suggest that starting haemodialysis incrementally at two sessions/ week is associated with lower mortality and better preservation of patients' remaining kidney function while offering many patient-important advantages, including dialysis free time and ability to work. however, robust evidence to recommend this incremental approach is lacking. the inch-hd study is an investigator-initiated, international, multicentre, prospective, adaptive, randomised, open-label, parallel group, non-inferiority trial. the primary objective of the study is to demonstrate whether incremental hd is non-inferior to conventional hd for the patient-important outcome of quality of life measured using kidney-specific component of the kidney disease quality of life - short form measurement (kdqol-sf) at 6 months from dialysis commencement. the study will recruit a total of 372 participants across hd centres in australia, and canada. the outcomes of this trial will will provide urgently needed high quality evidence on whether starting haemodialysis incrementally at two sessions/week compared to the conventional three sessions/week can safely reduce the physical, financial and quality-of life burden on patients, lower early mortality rates and slow loss of kidney function while increasing haemodialysis capacity and reducing costs.

Eligibility criteria:
inclusion criteria: 1. adults (≥ 18 years of age) and 2. commencing hd as their initial dialysis therapy and 3. able to give informed consent exclusion criteria: 1. urine output \<0.5litres/day 2. unlikely to be on hd for ≥1 year.

Keywords: incremental hd incident hd
sofosbuvir (gs-7977) in combination with peg and ribavirin for 12 weeks in treatment experienced subjects with chronic hcv infection genotype 2 or 3

Conditions: Hepatitis C

Summary: this study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (sof) in combination with peginterferon alfa 2a (peg) and ribavirin (rbv) administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis c virus (hcv) infection who have previously failed prior treatment with an interferon-based regimen.


Eligibility criteria:
inclusion criteria: * infection with genotype 2 or 3 hcv infection * cirrhosis determination * individual is treatment-experienced * screening laboratory values within defined thresholds * individual has not been treated with any investigational drug or device within 30 days of the screening visit * use of highly effective contraception methods if female of childbearing potential or sexually active male exclusion criteria: * prior exposure to a direct-acting antiviral drug targeting the hcv ns5b polymerase * pregnant or nursing female or male with pregnant female partner * current or prior history of clinical hepatic decompensation * history of clinically-significant illness or any other major medical disorder that may interfere with treatment, assessment, or compliance with the study protocol * excessive alcohol ingestion or significant drug abuse

Keywords: hcv genotype 2 (gt-2) hcv genotype 3 (gt-3) hcv sustained virologic response direct acting antiviral combination therapy treatment-naïve gs-7977 ribavirin rbv peginterferon alfa 2a peg additional relevant mesh terms: hepatitis hepatitis a hepatitis, chronic hepatitis c hepatitis c, chronic liver diseases digestive system diseases hepatitis, viral, human virus diseases enterovirus infections picornaviridae infections rna virus infections flaviviridae infections peginterferon alfa-2a interferon-alpha antiviral agents anti-infective agents therapeutic uses pharmacologic actions antimetabolites molecular mechanisms of pharmacological action immunologic factors physiological effects of drugs
rehabilitation training games for children with amblyopia

Conditions: Amblyopia; Amblyopia Occlusion; Child Behavior; Adherence, Treatment

Summary: a gamification product was developed to guide children with amblyopia to develop rehabilitation training habits by combining cognitive evaluation theory and occlusion therapy. a randomized controlled trial was conducted to examine the ease of use, acceptability and treatment compliance of the game.

the experimental group was subjected to a 20-minute daily, 4-week intervention experiment, which included a story background on the start page, eye patches to be put on according to the guidelines, fine eye training, and visual stimulation training, with short breaks between the different modes. the control group was given an experimental intervention using a competing product, with the same duration and format as the experimental group. after completion of the intervention, the participating children completed the mmas-8 adherence scale with the help of their parents.

Eligibility criteria:
inclusion criteria: * diagnosis of amblyopia (including refractive amblyopia, strabismic amblyopia and mixed). * the child has no significant iq deficits and has no difficulty communicating with others. * the children's teachers and parents gave their informed consent to participate in the experiment. the informed consent form was signed by the parents and is shown in the appendix. exclusion criteria: * severe amblyopia. * suffering from other psychological or physical disorders. * parents did not agree to sign the informed consent form or the child was not willing to participate in this experiment.
acute lymphoblastic leukaemia related to lenalidomide (lenall)

Conditions: Cancer

Summary: although lenalidomide (len) have proved effective in treating many cancers, few patients receiving len may experience rare but life-threatening adverse events such as acute lymphoblastic leukaemia (all). today, data about all are scarce. the objective was to investigate reports of all adverse events related to len in patients with cancer using the world health organization (who) pharmacovigilance database.


Eligibility criteria:
inclusion criteria: * case reported in the world health organization (who, also called vigibase) at the time of the extraction * patients treated with at least len (l04ax04) exclusion criteria: -chronology not compatible between len and all
in vivo detection of circulating clots in patients with thromboembolism

Conditions: Thromboembolism

Summary: subjects with thromboembolic disease or at high-risk for thromboembolic conditions diagnosed with ultrasound or other standard of care techniques will be recruited to estimate the feasibility of a device to detect in vivo cbcs.

there are no current gold standards to detect circulating blood clots. the sensitivity of most current methods to detect cbcs is poor when low numbers are present in the host. a novel method of detecting circulating blood clots, pafc, may improve detection of cbcs and, if so, ultimately may reduce complications related to previously undetected clots.

Eligibility criteria:
inclusion criteria * men and women, 18 years old and older. * evidence of current venous or arterial thromboembolic disease diagnosed by standard of care clinical, radiographic, or laboratory testing or acute ischemic stroke. * informed consent provided by the subject. exclusion criteria * pulmonary embolus with a need for mechanical ventilation or other ventilator support (may be on oxygen delivered by nasal cannula or mask at an fio2 of ≤ 0.40) * acute coronary syndrome (including unstable angina) * significant cardiac arrhythmia (may have atrial fibrillation controlled with medication) * intracardiac thrombus * any embolus or thrombus requiring vascular surgery or interventional radiology to attempt acute embolectomy or thrombectomy * sickle cell disease with vaso-occlusive crisis * sepsis or life-threatening infection * traumatic injury requiring hospitalization (within 30 days prior to enrollment) * pregnancy or breastfeeding * severe mental illness * other conditions deemed by the investigators to put the subject at greater risk
phase i study of jyp0322 in ros1 fusion-positive solid tumors

Conditions: Protein Kinase Inhibitors; Other Protocol Specified Criteria; Lung Neoplasms; Brain Neoplasms

Summary: an open, non-randomized, multicenter, single-arm dose-escalation design, phase 1 trial to study the safety, tolerability, pharmacokinetics and efficacy of jyp0322 in patients with ros1+ locally advanced/metastatic solid tumors .

jyp0322 is an orally available inhibitor of ros1 (coded by the gene ros1). molecular fusions are present in several different tumor types, including non-small cell lung cancer (nsclc), glioma, etc. patients with locally advanced or metastatic cancer with a detectable molecular fusion in targets of interest may be eligible for enrollment. phase 1 will assess safety and tolerability of jyp0322 via standard dose escalation scheme and determine the recommended phase 2 dose. safety and efficacy will be assessed in the dose expansion portion of the study.

Eligibility criteria:
key inclusion criteria * adult patients age 18 years or older. * histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a ros1 molecular fusion. * measurable disease according to recist version 1.1 * life expectancy of at least 3 months * other protocol specified criteria key exclusion criteria: * current participation in another therapeutic clinical trial. * gastrointestinal disease (e.g., crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption. * a history of severe allergies, or a history of severe allergy, hypersensitivity or other hypersensitivity to any active or inactive ingredient of the study drug. * known active infections (bacterial, viral including hiv positivity). * other protocol specified criteria

Keywords: ros1 fusions ros1 gene rearrangements primary brain tumors ros1
cardiovascular autonomic control evaluation through cardiac frequency variability in hypertensive patients

Conditions: Hypertension

Summary: analyzing cardiovascular evaluation measures in the multidisciplinary and in the conventional treatment of hypertensive patients will provide better parameters for comparing the two approaches.


Eligibility criteria:
inclusion criteria: * above 18 years of age * diagnosis of primary hypertension exclusion criteria: * neurological condition * cardiac condition * renal condition * congenital conditions * previous myocardial revascularization surgery

Keywords: cardiac frequency variability multidisciplinary care clinical trial
a study of mabthera (rituximab) in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Conditions: Rheumatoid Arthritis

Summary: this study will evaluate the safety and efficacy of mabthera in patients with active rheumatoid arthritis who have had an inadequate response or were intolerant to treatment with methotrexate. eligible patients will receive mabthera (1000mg by intravenous infusion) on days 1 and 15, and background methotrexate (oral or subcutaneous dose of 10-25mg weekly). after the initial study period of 24 weeks, eligible patients may receive up to 3 re-treatments with mabthera. the anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * receiving out-patient treatment; * experienced an inadequate response to previous or current treatment with methotrexate. exclusion criteria: * rheumatic autoimmune disease other than ra, or significant systemic involvement secondary to ra; * history of, or current, inflammatory joint disease other than ra; * previous treatment with any cell-depleting therapies.